CrowdStrike stock slips after judge tosses outage lawsuit as CRWD pushes deeper into browser security
14 January 2026
2 mins read

CrowdStrike stock slips after judge tosses outage lawsuit as CRWD pushes deeper into browser security

New York, Jan 14, 2026, 14:47 ET — Regular session

CrowdStrike Holdings’ stock fell 1.7% to $459.98 on Wednesday afternoon after a U.S. judge dismissed a shareholder fraud lawsuit stemming from the cybersecurity firm’s July 2024 outage. U.S. District Judge Robert Pitman said investors failed to show the company or its executives misled them about software testing before an update crashed more than 8 million Microsoft Windows computers. The New York State Common Retirement Fund, led by Comptroller Thomas DiNapoli, said the decision was “under review,” while CrowdStrike’s chief legal officer Cathleen Anderson welcomed the dismissal; Delta Air Lines’ separate suit tied to the outage remains active. 1

The ruling trims a headline legal risk for a company that’s still living with the aftertaste of a very public operational failure. For investors, it’s less about one case and more about whether the outage-era questions — controls, process, speed — fade into the background or keep resurfacing.

It also lands as software stocks wobble again, with buyers quick to punish anything that smells like execution risk. CrowdStrike has spent years pitching itself as a platform company, and platform stories tend to break hardest when the market turns picky.

On Tuesday, CrowdStrike said it signed a definitive agreement to acquire Seraphic Security, a browser runtime security firm, as it tries to extend its Falcon platform into the web browser — a growing target for phishing and session hijacking. “By decoupling security from the browser itself, we can turn any browser into a secure enterprise browser,” CEO George Kurtz said. CrowdStrike said the purchase price is expected to be paid predominantly in cash, with a portion in stock subject to vesting, and the deal is expected to close during CrowdStrike’s first quarter of fiscal 2027; Seraphic CEO Ilan Yeshua said joining CrowdStrike would bring “platform-level protection” to the browser. 2

CrowdStrike’s move came as cybersecurity and broader tech shares slid, leaving little room for a clean “legal win” trade. Palo Alto Networks fell 0.8%, Fortinet dropped 2.3% and Zscaler lost 2.7%, while the Invesco QQQ Trust — a proxy for Nasdaq-heavy tech — was down about 1.5%.

The deal focus puts competitive pressure back on product breadth. Customers already juggle endpoint tools, identity controls and cloud defenses; browser-layer security is another budget line unless CrowdStrike can bundle it in a way that actually reduces sprawl.

But the downside case is still easy to sketch. Litigation can drag even after a dismissal, and more deal-making raises the odds of integration hiccups or margin noise — the kind of stuff that gets amplified when the tape is weak.

Investors now look toward the company’s next set of updates around its fiscal year-end on Jan. 31, and any additional detail on timing and integration for the Seraphic transaction. CrowdStrike is also scheduled to run a virtual AI Summit on Jan. 21 and its Fal.Con Gov 2026 event in Washington on March 18 — venues where executives often sharpen product messaging for customers and, by extension, the market. 3

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:49 AM EST CSL Faces Growth Uncertainty Amid Seqirus Spin-off Pause and Flu Vaccine Demand Drop February 7, 2026, 12:49 AM EST. CSL (ASX:CSL) confronts near-term challenges after delaying its Seqirus vaccine unit spin-off due to weaker U.S. flu vaccination uptake, impacting its fiscal 2026 growth outlook. Regulatory scrutiny in Europe over its Tavneos kidney therapy data, plus intensifying U.S. competition for its Vifor iron products, heighten concerns over product credibility and pricing pressure. Despite these headwinds, CSL's diversified portfolio in plasma, vaccines, and kidney therapies underpins its
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Gold price hits $4,641 record as Powell probe and Fed cut bets send silver above $92
Previous Story

Gold price hits $4,641 record as Powell probe and Fed cut bets send silver above $92

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Next Story

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Go toTop